Patients who had adjuvant Verzenio with endocrine therapy had a small but significant improvement in survival versus endocrine therapy alone.

Patients who had adjuvant Verzenio with endocrine therapy had a small but significant improvement in survival versus endocrine therapy alone.

The agency launched the Commissioner's National Priority Voucher pilot program to quickly approve products that could address national interests.

Trial initiation triggered a $250 million payment to SystImmune from Bristol Myers Squibb, under a 2023 collaboration and license agreement.

Kite has paid $120 million upfront to Pregene to gain certain license rights and to collaborate on developing in vivo cell therapies with the Shenzen, China-based firm. Pregene is entitled to receive ...